Market Overview:
The global transdermal scopolamine market is expected to grow at a CAGR of 5.5% from 2018 to 2030. The growth in the market can be attributed to the increasing prevalence of chronic diseases, rising geriatric population, and technological advancements in the field of transdermal drug delivery systems. Based on type, the global transdermal scopolamine market is segmented into tablet type, syrups type, injections type, patch type, and gel type. The tablet type segment is expected to account for the largest share of the global transdermal scopolamine market in 2018. This can be attributed to factors such as ease-of-use and growing demand for prescription drugs over OTC drugs. Based on application, narcotic analgesia accounts for the largest share of the global transdermal scopolamine market followed by cough and asthma applications respectively.
Product Definition:
A medication used to treat nausea and vomiting. It is a transdermal patch that is placed on the skin and releases scopolamine into the bloodstream. This medication is important because it can help to relieve nausea and vomiting, which can be a common side effect of chemotherapy or radiation therapy.
Tablet Type:
Tablet type is the most common form of transdermal scopolamine. It is a solid, elongated and narrow tablet containing anywhere from 1 to 10 mg of scopolamine. They are colorless and odorless which makes them ideal for topical application. The tablets can be administered by themselves or in combination with other drugs depending on the condition being treated (antiparkinson, anti-epileptic).
Syrups Type:
Syrups type is a solution of glucose and sucrose in water. It is widely used as an adjuvant for transdermal scopolamine. The product has the ability to reduce pain, anxiety, and restlessness during sleep induction by acting on voltage-gated sodium channels of the brainstem.
Application Insights:
The others segment held the largest share of application in 2016. This includes anxiety, depression, arthritis pain and others. Transdermal scopolamine is used for treating these disorders as it blocks the action of acetylcholine which causes drowsiness and reduces mental alertness. The Parkinson¢â‚¬â„¢s disease treatment segment is expected to grow at a significant rate over the forecast period owing to high patient awareness regarding PD treatment options due to increased research activities by pharmaceutical companies & government support in various countries such as U.S., China, India etc.
The cough application segment is also expected to witness lucrative growth during the forecast period due to its high usage rates particularly in developed countries like U.S.
Regional Analysis:
North America dominated the global market in 2017. The region is expected to witness a CAGR of XX% during the forecast period. This can be attributed to various factors such as increasing prevalence of chronic pain, neurological disorders, and other diseases; rising awareness about transdermal drug delivery systems; and presence of major players in this region. Moreover, high disposable income is also anticipated to drive growth during the forecast period.
Asia Pacific market for tranedermal scopolamine is anticipated to grow at a significant rate during the forecast period owing to presence of large patient pool suffering from motion sickness due tp travel or surgery coupled with increasing healthcare expenditure by governments & private sectors for treatment related issues along with growing medical tourism industry in this region which will boost demand for narcotic analgesics including scopolamine patch/injections etc., thereby driving growth over the projected time frame.
Growth Factors:
- Increasing geriatric population: The global geriatric population is increasing at a rapid pace. This is expected to drive the demand for transdermal scopolamine in the coming years.
- Growing prevalence of chronic diseases: The prevalence of chronic diseases such as dementia, Alzheimer's disease, and Parkinson's disease is increasing rapidly across the world. This is likely to boost the demand for transdermal scopolamine in the near future.
- Rising awareness about benefits of transdermal scopolamine: There has been a rise in awareness about the benefits of using transdermal scopolamine among patients and healthcare professionals in recent years. This is likely to propel its market growth during the forecast period.
Scope Of The Report
Report Attributes
Report Details
Report Title
Transdermal Scopolamine Market Research Report
By Type
Tablet Type, Syrups Type, Injections Type, Patch Type, Gel Type
By Application
Narcotic Analgesia, Cough, Asthma, Motion Sickness, Parkinson's Disease, Others
By Companies
Baxter International, GlaxoSmithKline, Novartis AG, Perrigo Company, Caleb Pharmaceuticals, Myungmoon Pharma, Pfizer, Nichi-Iko
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
169
Number of Tables & Figures
119
Customization Available
Yes, the report can be customized as per your need.
Global Transdermal Scopolamine Market Report Segments:
The global Transdermal Scopolamine market is segmented on the basis of:
Types
Tablet Type, Syrups Type, Injections Type, Patch Type, Gel Type
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Narcotic Analgesia, Cough, Asthma, Motion Sickness, Parkinson's Disease, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Baxter International
- GlaxoSmithKline
- Novartis AG
- Perrigo Company
- Caleb Pharmaceuticals
- Myungmoon Pharma
- Pfizer
- Nichi-Iko
Highlights of The Transdermal Scopolamine Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Tablet Type
- Syrups Type
- Injections Type
- Patch Type
- Gel Type
- By Application:
- Narcotic Analgesia
- Cough
- Asthma
- Motion Sickness
- Parkinson's Disease
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Transdermal Scopolamine Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Transdermal scopolamine is a medication that is applied to the skin. It works by blocking nerve impulses from spreading through the body. This can help relieve symptoms of anxiety and depression.
Some of the major players in the transdermal scopolamine market are Baxter International, GlaxoSmithKline, Novartis AG, Perrigo Company, Caleb Pharmaceuticals, Myungmoon Pharma, Pfizer, Nichi-Iko.
The transdermal scopolamine market is expected to grow at a compound annual growth rate of 5.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Transdermal Scopolamine Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Transdermal Scopolamine Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Transdermal Scopolamine Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Transdermal Scopolamine Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Transdermal Scopolamine Market Size & Forecast, 2018-2028
4.5.1 Transdermal Scopolamine Market Size and Y-o-Y Growth
4.5.2 Transdermal Scopolamine Market Absolute $ Opportunity
Chapter 5 Global Transdermal Scopolamine Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Transdermal Scopolamine Market Size Forecast by Type
5.2.1 Tablet Type
5.2.2 Syrups Type
5.2.3 Injections Type
5.2.4 Patch Type
5.2.5 Gel Type
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Transdermal Scopolamine Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Transdermal Scopolamine Market Size Forecast by Applications
6.2.1 Narcotic Analgesia
6.2.2 Cough
6.2.3 Asthma
6.2.4 Motion Sickness
6.2.5 Parkinson's Disease
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Transdermal Scopolamine Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Transdermal Scopolamine Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Transdermal Scopolamine Analysis and Forecast
9.1 Introduction
9.2 North America Transdermal Scopolamine Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Transdermal Scopolamine Market Size Forecast by Type
9.6.1 Tablet Type
9.6.2 Syrups Type
9.6.3 Injections Type
9.6.4 Patch Type
9.6.5 Gel Type
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Transdermal Scopolamine Market Size Forecast by Applications
9.10.1 Narcotic Analgesia
9.10.2 Cough
9.10.3 Asthma
9.10.4 Motion Sickness
9.10.5 Parkinson's Disease
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Transdermal Scopolamine Analysis and Forecast
10.1 Introduction
10.2 Europe Transdermal Scopolamine Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Transdermal Scopolamine Market Size Forecast by Type
10.6.1 Tablet Type
10.6.2 Syrups Type
10.6.3 Injections Type
10.6.4 Patch Type
10.6.5 Gel Type
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Transdermal Scopolamine Market Size Forecast by Applications
10.10.1 Narcotic Analgesia
10.10.2 Cough
10.10.3 Asthma
10.10.4 Motion Sickness
10.10.5 Parkinson's Disease
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Transdermal Scopolamine Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Transdermal Scopolamine Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Transdermal Scopolamine Market Size Forecast by Type
11.6.1 Tablet Type
11.6.2 Syrups Type
11.6.3 Injections Type
11.6.4 Patch Type
11.6.5 Gel Type
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Transdermal Scopolamine Market Size Forecast by Applications
11.10.1 Narcotic Analgesia
11.10.2 Cough
11.10.3 Asthma
11.10.4 Motion Sickness
11.10.5 Parkinson's Disease
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Transdermal Scopolamine Analysis and Forecast
12.1 Introduction
12.2 Latin America Transdermal Scopolamine Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Transdermal Scopolamine Market Size Forecast by Type
12.6.1 Tablet Type
12.6.2 Syrups Type
12.6.3 Injections Type
12.6.4 Patch Type
12.6.5 Gel Type
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Transdermal Scopolamine Market Size Forecast by Applications
12.10.1 Narcotic Analgesia
12.10.2 Cough
12.10.3 Asthma
12.10.4 Motion Sickness
12.10.5 Parkinson's Disease
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Transdermal Scopolamine Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Transdermal Scopolamine Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Transdermal Scopolamine Market Size Forecast by Type
13.6.1 Tablet Type
13.6.2 Syrups Type
13.6.3 Injections Type
13.6.4 Patch Type
13.6.5 Gel Type
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Transdermal Scopolamine Market Size Forecast by Applications
13.10.1 Narcotic Analgesia
13.10.2 Cough
13.10.3 Asthma
13.10.4 Motion Sickness
13.10.5 Parkinson's Disease
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Transdermal Scopolamine Market: Competitive Dashboard
14.2 Global Transdermal Scopolamine Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Baxter International
14.3.2 GlaxoSmithKline
14.3.3 Novartis AG
14.3.4 Perrigo Company
14.3.5 Caleb Pharmaceuticals
14.3.6 Myungmoon Pharma
14.3.7 Pfizer
14.3.8 Nichi-Iko
